Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma
Official title: Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Run by Indiana University · NCT07847073 · Data updated 2026-11-12
In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 13 (estimated) |
| Sponsor | Indiana University Academic / other |
| Locations | 1 site (Bloomington, Indiana) |
| Status | Recruiting |
| Started | October 2026 |
| Main results expected | January 2028 |
| Study ends | January 2028 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT07847073 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older with open-angle glaucoma, suitable visual acuity, and not currently on conflicting therapies, who can complete a 12-month crossover protocol.
✕Probably not a fit
Patients who do not show differential retinal protection or who experience adverse effects may not benefit beyond standard IOP control.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, investigator-mmasked, crossover pilot trial comparing netarsudil (Rhopressa) and timolol in adults with open-angle glaucoma. Participants will use each medication for six months in random order, with regular visits to measure intraocular pressure and retinal structure. High-resolution AO-OCT imaging will track individual retinal ganglion cell layer changes over time to see if Rhopressa offers neuroprotection beyond pressure lowering. The study aims to determine if Rhopressa can reduce ganglion cell loss while maintaining similar IOP reduction to Timolol.
Why it matters
Potential benefit: If successful, Rhopressa could offer added protection of retinal nerve cells for glaucoma patients.
How similar studies have gone: Prior work suggests potential neuroprotective effects of ROCK inhibitors, but direct cell-level protection with clinical imaging has not been clearly demonstrated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All subjects will be 18 years of age or older * Subjects must be diagnosed with open-angle glaucoma and have had an eye exam within the past year * Subjects with glaucoma will have structural (optic nerve and retinal nerve fiber layer) and functional (visual field testing) defects consistent with the diagnosis of glaucoma * Subjects will have a corrected acuity of 20/50 or better and be able to fixate * Naïve to medication subjects or post washout IOP between 18 and 34 mmHg * Spherical equivalent from +3 diopters to -6 diopters, with a cylinder of \<-3 diopters * Subject is willing and able to comply with the protocol requirements and to remain in the study for its full duration, including all scheduled visits and follow-up assessments Exclusion Criteria: * Subjects with a known intolerance to netarsudil ophthalmic solution * Subjects with a known intolerance to, or contraindication for, timolol maleate * Any subject whom the investigator determines to be at unacceptable risk for the washout or believes is unlikely to complete the study * Subjects with retinal disease or optic neuropathies other than glaucoma that, in the opinion of the investigator, could confound the study assessments or outcome * Female subjects who are pregnant, breastfeeding, or of childbearing age who are not sterile or using an acceptable method of contraception during the study
Where it's running
-
Indiana University School Of Optometry
Bloomington, Indiana, United States Recruiting
Study contacts
- Study coordinator: Brett J King, OD, FAAO, Dipl AAO (Glaucoma)
- Email: kingbrj@iu.edu
- Phone: (812) 855-1344
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the long-term safety and effectiveness of a modified silicone tube for glaucoma treatment
This study is testing a new silicone tube to see if it safely helps people with glaucoma manage their eye pressure and maintain good vision over the long term.
-
Balance training for people with glaucoma
A randomized study tests whether a structured eight-week balance program helps adults with glaucoma improve balance, reduce fall risk, and lessen fear of falling.
-
iDose TR implant administration in an office-based eye clinic
This study tests a travoprost implant (iDose TR) given inside the eye to people with open-angle glaucoma or high eye pressure in an office setting to see if it is safe.
-
Comparison of FT-1000 non-contact tonometry with Goldmann applanation tonometry in glaucoma patients
This study tests whether the FT-1000 non-contact tonometer gives measurements that agree with the Goldmann applanation tonometer in adults with glaucoma.
-
Removing the ripcord from a glaucoma drainage device after 3 months
This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.
-
Glaucoma and Brain Changes: How Brain Structure and Size See What Glaucoma Is Doing
This study tests whether glaucoma is linked to broader brain changes by comparing brain MRI and eye health over time in people with glaucoma and matched controls.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.